Healthcare Industry News:  antiplatelet therapy 

Devices Interventional Cardiology Personnel

 News Release - December 10, 2015

Antonio Colombo, MD appointed Member of the Scientific Advisory Council of Miracor Medical Systems

“PiCSO is one of the most exciting new therapies for the treatment of acute myocardial infarction” (Prof. Antonio Colombo, Milan, Italy)

VIENNA--(Healthcare Sales & Marketing Network)--Miracor Medical Systems GmbH (Miracor) announced that Antonio Colombo, MD, FACC, FESC, FSCAI from Milan, Italy, has joined its Scientific Advisory Council which already includes thought leaders such as Dr. Gregg Stone, Dr. Azfar Zaman, Dr. Adrian Banning, Dr. Malte Kelm, Dr. Tienush Rassaf, and Dr. Werner Mohl.

Prof. Colombo is Director of the Cardiac Catheterization Laboratory at EMO GVM Centro Cuore Columbus and Chief of Invasive Cardiology at San Raffaele Hospital, both in Milan, Italy, and Visiting Professor of Medicine at Columbia Medical Center in New York, USA. He is a leading innovator and pioneer in interventional cardiology and has contributed significantly to today’s use of coronary stents and defined the role of intravascular ultrasound in this setting. In addition, his studies along with others have redefined adequate antiplatelet therapy after coronary stenting.

“It is with pleasure and excitement that I join the Scientific Advisory Council of Miracor,” says Prof. Antonio Colombo. “The PiCSO Impulse system is one of the most exciting new therapies in the area of acute myocardial infarction treatment and I also see a huge potential beyond this indication. I look forward to collaborating with the Council’s other members and to contributing significantly to the further establishment of PiCSO in clinical practice and the investigation of its benefits in other indications,” he continues.

The PiCSOAMIImpulse System is designed for use during coronary revascularization procedures following myocardial infarction and other types of acute coronary syndrome to intermittently increase the pressure in the coronary venous system and thereby increase myocardial perfusion, improve cardiac function, and reduce damage to the heart.

“We are honored to have Prof. Colombo actively participating in Miracor’s Scientific Advisory Council. He is a true pioneer in cardiology and his expertise is invaluable for the further establishment of PiCSO therapy,” says Werner Braun, CEO of Miracor. “Miracor is dedicated to improving clinical outcome of patients with impaired cardiac function. We look forward to having Prof. Colombo contribute to this.”

About Miracor Medical Systems GmbH

Based in Vienna, Austria, Miracor Medical Systems GmbH ( provides innovative solutions for the treatment of severe cardiac diseases, aiming to improve short and long-term clinical outcome and reduce associated cost.

Miracor markets the PiCSO® Impulse System, the first and only coronary sinus intervention designed to improve cardiac function, reduce infarct size, and prevent the development of heart failure following acute myocardial infarction. The CE-marked system is currently commercially available in the EU and selected countries in the Middle-East.

NOTE: The CE marked PiCSO® Impulse System is approved for sale in Europe.

It is currently not approved for commercial or investigational use in the United States.

Source: Miracor Medical Systems

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.